Metis Global Partners LLC Boosts Stock Position in Edwards Lifesciences Co. (NYSE:EW)

Metis Global Partners LLC boosted its holdings in Edwards Lifesciences Co. (NYSE:EW) by 7.0% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 44,111 shares of the medical research company’s stock after buying an additional 2,902 shares during the quarter. Metis Global Partners LLC’s holdings in Edwards Lifesciences were worth $3,266,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of EW. Migdal Insurance & Financial Holdings Ltd. purchased a new position in shares of Edwards Lifesciences during the fourth quarter worth about $30,000. FSA Wealth Management LLC purchased a new position in shares of Edwards Lifesciences during the third quarter worth about $30,000. Prospera Private Wealth LLC purchased a new position in shares of Edwards Lifesciences during the third quarter worth about $32,000. Avior Wealth Management LLC grew its holdings in shares of Edwards Lifesciences by 138.7% during the third quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company’s stock worth $35,000 after purchasing an additional 308 shares during the last quarter. Finally, Roble Belko & Company Inc purchased a new position in shares of Edwards Lifesciences during the fourth quarter worth about $46,000. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Insider Transactions at Edwards Lifesciences

In other news, CFO Scott B. Ullem sold 11,250 shares of the business’s stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price of $75.76, for a total transaction of $852,300.00. Following the sale, the chief financial officer now owns 30,561 shares of the company’s stock, valued at $2,315,301.36. The trade was a 26.91 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Daniel J. Lippis sold 500 shares of the company’s stock in a transaction that occurred on Thursday, January 16th. The shares were sold at an average price of $68.76, for a total value of $34,380.00. Following the completion of the sale, the vice president now directly owns 23,189 shares in the company, valued at approximately $1,594,475.64. The trade was a 2.11 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 37,739 shares of company stock valued at $2,799,104 in the last quarter. 1.29% of the stock is currently owned by corporate insiders.

Edwards Lifesciences Stock Performance

NYSE EW opened at $71.61 on Friday. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. The business’s 50 day moving average is $72.64 and its two-hundred day moving average is $70.27. Edwards Lifesciences Co. has a 12-month low of $58.93 and a 12-month high of $96.12. The stock has a market capitalization of $42.24 billion, a price-to-earnings ratio of 10.27, a PEG ratio of 4.82 and a beta of 1.10.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Tuesday, February 11th. The medical research company reported $0.59 EPS for the quarter, topping the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. Research analysts expect that Edwards Lifesciences Co. will post 2.45 EPS for the current year.

Analyst Upgrades and Downgrades

EW has been the topic of several research reports. The Goldman Sachs Group raised their price objective on Edwards Lifesciences from $81.00 to $90.00 and gave the stock a “buy” rating in a report on Thursday, December 5th. Truist Financial reaffirmed a “hold” rating and set a $78.00 price objective (up previously from $70.00) on shares of Edwards Lifesciences in a report on Thursday, December 5th. Bank of America raised Edwards Lifesciences from a “neutral” rating to a “buy” rating and raised their price target for the stock from $82.00 to $90.00 in a report on Monday, December 16th. Evercore ISI lowered their price target on Edwards Lifesciences from $75.00 to $73.00 and set an “in-line” rating on the stock in a report on Wednesday, February 12th. Finally, Piper Sandler raised their price target on Edwards Lifesciences from $70.00 to $73.00 and gave the stock a “neutral” rating in a report on Wednesday, February 12th. One investment analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and twelve have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $79.95.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.